Introduction
The protease inhibitors approved as anti-HIV-1 drugs are linear peptide mimetics with a central secondary hydroxy group binding to the catalytic aspartic acid residues and mimicking the oxygen in the tetrahedral transition state for amide cleavage (Wlodawer & Vondrasek, 1998) . Although their overall structures are quite different, they all have a large aromatic group in the S1-or S1′-position, analogous to the structure of the substrate. However, the resistance profiles of the clinical inhibitors vary. In patient isolates, resistant virus with G48V ( Jacobsen et al., 1996; Craig et al., 1998) and L90M substitutions in the protease ( Jacobsen et al., 1996; Craig et al., 1998; Cabana et al., 1999; Condra et al., 2000; Gulick et al., 2000) were found under the selective pressure of saquinavir. While ritonavir and indinavir result in resistant virus with a V82A substitution (Gulnik et al., 1995; Cabana et al., 1999; Koch et al., 1999; Condra et al., 2000) , ritonavir also selects for I84V substituted enzyme (Gulnik et al., 1995; Cabana et al., 1999; Condra et al., 2000) , nelfinavir for D30N and N88D substituted enzymes (Patick et al., 1998) and amprenavir for I50V (Partaledis et al., 1995) . Multiresistant strains usually contain a number of different mutations, of which double mutants G48V/L90M ( Jacobsen et al., 1995; Palmer et al., 1999) and I84V/L90M (Olsen et al., 1999; Palmer et al., 1999) have been reported frequently.
Although the structural features that are associated with a certain resistance profile are not known, a strategy based on inhibitors with significantly different structures than those in clinical use is expected to circumvent the resistance that results from the inhibitors used currently. So far, there are no cyclic inhibitors on the market, although cyclic urea and cyclic sulfamide inhibitors with nanomolar K i values have been reported (Lam et al., 1994 Hodge et al., 1996; Hultén et al., 1997 Hultén et al., ,1999 Rodgers et al., 1998; Schaal et al, 2001) . These compounds were designed to replace not only the substrate, but also the structural water, forming a bridge between the inhibitor and the flaps of the enzyme. This design results in a rigid central core structure that can be substituted with P1/P1′ and P2/P2′ groups that bind to the corresponding substrate-binding sites of the enzyme in a manner resembling the linear compounds. Despite a close structural similarity, the structure-inhibitory properties of the cyclic ureas and sulfamides are quite distinct, since the central core is twisted in the sulfamide, resulting in a flip in the binding of the P1′-and P2′-groups (Bäckbro et al., 1997) . In this work we initially addressed the structure-inhibitory properties of a series of cyclic sulfamide analogues, and compared their inhibition profiles with those of cyclic urea and linear transition state analogues, including inhibitors in clinical use. For this purpose, mutant HIV-1 protease with single, double, triple and quadruple combinations of G48V, V82A, I84V and L90M substitutions were introduced into the enzyme, corresponding to mutations associated with clinical resistance. In addition, the large set of inhibition data, obtained with a series of structurally related and unrelated inhibitors, and a panel of mutants, was extensively analysed with the aim to reveal some of the structural features associated with a certain inhibition profile.
Materials and methods

Preparation and characterization of HIV-1 protease
Mutants G48V, V82A, I84V, L90M and G48V/L90M were obtained by point mutating the gene coding for the wild-type enzyme from strain HXB; they were cloned and purified as previously described . The I84V/L90M, V82A/I84V/L90M and G48V/V82A/I84V/L90M mutants were constructed using a QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, Calif., USA). The method is based on temperature cycling of a vector containing the template gene and two synthetic oligonucleotide primers (Operon, Alameda, Calif., USA) containing the desired mutation. The following primers were used (restriction sites underlined, mutations in bold): L90M: primer 1: 5′-CCT GTC AAC ATA ATT GGA AGG AAT CTG ATG ACT CAG ATT GGT TGC -3′ (TfiI introduced), primer 2: 5′-GCA ACC AAT CTG AGT CAT CAG ATT CCT TCC AAT TAT GTT GAC AGG -3′ (TfiI introduced). I84V: primer 3: 5′-GGT ACA GTA TTA GTA GGC CCT ACA CCT GTC AAC GTA ATT GGA AG-3′ (AvaII removed), primer 4: 5′-CTT CCA ATT ACG TTG ACA GGT GTA GGG CCT ACT AAT ACT GTA CC-3′ (AvaII removed). V82A/I84V: primer 5: 5′-GGT ACA GTA TTA GTA GGC CCT ACA CCT GCC AAC GTA ATT GGA AG-3′ (AvaII removed), primer 6: 5′-CTT CCA ATT ACG TTG GCA GGT GTA GGG CCT ACT AAT ACT GTA CC-3′ (AvaII removed). G48A: primer 7: 5′-GCC AGG AAG ATG GAA ACC CAA AAT GAT AGT GGG AAT TGG AGG-3′ (XcmI introduced), primer 8: 5′-CCT CCA ATT CCC ACT ATC ATT TTG GGT TTC CAT CTT CCT GGC-3′ (XcmI introduced).
The HIV-1 protease gene, in the plasmid pGEM3zf(+), was subjected to multiple rounds of mutagenesis to obtain the desired mutations. The first round, using the primers 1 and 2 produced the L90M mutant, which was used as template for the double and triple mutants. A second round, using primers 3 and 4, yielded the double mutant I84V/L90M. A different second round, using primers 5 and 6, yielded the triple mutant V82A/I84V/L90M, which was used as a template for a third round, using primers 7 and 8, resulting in the quadruple mutant G48V/V82A/I84V/L90M. Pfu polymerase was used during thermal cycling to minimize the introduction of unwanted mutations, and non-mutated DNA was digested with DpnI. Clones containing the mutations were selected by digestion with endonucleases whose cleavage site was introduced or removed by silent mutation (see above). The mutations were verified by dideoxy sequencing. The mutated gene was excised using NdeI and BamHI digestion, and subcloned into corresponding sites in pET11-a (Novagen, Madison, Wis., USA).
Expression and purification of mutants was performed essentially as described for the wild-type enzyme . The concentration of active enzyme was determined by titration with the inhibitor showing the lowest K i value (see below). All measurements were carried out at 30°C in 0.1 M acetate 1 M NaCl, pH 5.0 and 5% v/v DMSO, essentially as described , using substrate concentrations of 1.5, 3, 5, 8 and 12 µM and four different enzyme concentrations for each mutant. For the I84V/L90M double mutant, substrate concentrations of 1.5, 3.1, 6.2 and 12.5 µM were used instead. All determinations were carried out in quadruplicates, and kinetic constants were estimated by non-linear regression using the Michaelis-Menten equation and the GraFit program version 4.0 (Erithacus Software, Staines, UK). The catalytic efficiency, k cat /K M , was calculated for each enzyme concentration, and for each enzyme the average value was used. The presented k cat and K M values are average values for each enzyme.
Inhibitors
Cyclic inhibitors (Table 1) were synthesized as previously published (Hultén et al., ,1999 Schaal et al., 2001) . Linear inhibitors B322 [compound 48 (Alterman et al., 1998) ], B388 (compound 4 Andersson et al., unpublished results), B403 (Pyring et al., 2001) and B428 [compound 9 (Alterman et al., 1999) ] are shown in Figure 1 . Saquinavir was obtained from Roche Registration (Herts, UK), ritonavir from Abbott Laboratories (Kent, UK), indinavir from Merck Sharp & Dome (Herts, UK), nelfinavir from Agouron Pharmaceuticals (La Jolla, Calif., USA), and amprenavir from Vertex Pharmaceuticals (Cambridge, Mass., USA).
Inhibition studies
Inhibitory potencies were determined as K i values essentially as described for determination of k cat /K M values (above) using five concentrations of each inhibitor. The lowest possible enzyme concentration was used, varying between 1 and 50 nM. K i values were determined by non-linear regression using the GraFit program version 4.0 and an algorithm for tight-binding inhibitors as previously described .
Results
Catalytic properties of mutant enzymes
To allow a comparison of the effect of inhibitors on mutant enzyme, it was necessary to take the altered catalytic efficiency into account. The kinetic properties of wild-type and mutant enzyme were therefore determined (Table 2) . The catalytic efficiencies of the single and double mutants were 10-30% of the wild-type enzyme efficiency due to a combination of a reduction in k cat and an increase in K M . A further 10-fold decrease in catalytic efficiency was observed for the triple and quadruple mutants. These mutants displayed the lowest catalytic rates, and the quadruple mutant had the highest K M -value, being almost five times higher than that of the wild-type enzyme. In addition, the mutants generally had a reduced level of expression and were less stable than the wild-type enzyme, although these properties were not quantified.
Enzyme inhibition
One of the aims of this study was to evaluate the resistance profile of cyclic sulfamide inhibitors. The inhibition of wild-type HIV-1 protease and V82A, I84V and G48V/L90M mutants by a series of symmetric and asymmetric cyclic sulfamide inhibitors, with variations in the P2/P2′ side chain, and three analogous cyclic urea inhibitors, were determined ( Table 3 ). The same structural features that increased the affinity of the cyclic sulfamide inhibitors for the wild-type enzyme also increased the affinity for the V82A, I84V and G48V/L90M mutants. Only a few obvious exceptions were identified; A022 had higher affinity for the V82A and G48V/L90M mutants than predicted from the affinity for the wild-type enzyme, as did A010 for the G48V/L90M mutant and A051 for the I84V and the G48V/L90M mutant. Other exceptions resulted in lower affinity than predicted from the inhibition of the wild-type enzyme (A044, A027, A025 and A020). Overall, the I84V mutant was least sensitive to inhibition by the cyclic inhibitors, and the G48V/L90M double mutation had the smallest effect on inhibition. Also, for all variants of the enzyme studied, the effect of enlarging the P2/P2′ side chain in the cyclic urea series (from A001 <A008 <A010) was paralleled in the sulfamide series (from A006 <A021 <A022). The largest P2/P2′ side chain reduced the affinity more for the cyclic urea compounds than for the sulfamides.
The most potent cyclic inhibitors were studied further using an extended panel of mutants ( Table 3 ). The K i values for a series of linear inhibitors, including the compounds used as drugs, were also determined. With only two exceptions (A024 and A030 with L90M), and within experimental error, all inhibitors had the same or higher K i values with the mutants than with the wild-type enzyme. All linear inhibitors and the cyclic A008 yielded an inhibition of the wild-type enzyme comparable to the clinical substances, but all other compounds showed at least an order of magnitude higher K i values.
The S1/S1′ mutation G48V, a common resistance mutation, resulted in at least a 10-fold reduction of the inhibition by B403, saquinavir and indinavir, while it had little effect on the other inhibitors. Compounds B403, saquinavir and indinavir are structurally distinct. Also situated in the S1/S1′ site, the V82A mutation decreased the inhibition at least 10-fold towards A008 (and many of the less potent cyclic compounds), B322, nelfinavir and indinavir; again a set of inhibitors with no obvious structural relationship. I84V, a mutation in the S2/S2′ site, reduced the inhibition by all cyclic and linear inhibitors tested, although the exact amount is undetermined for many compounds due to large errors. Finally, the L90M mutation reduced the inhibitory effect of all inhibitors, except B322, A024 and A030, with the latter two actually being at least twofold more efficient with this mutant than with the wild-type enzyme.
When mutations were combined, the effects were even less related to structural class and could not be predicted from the combination of mutations in a certain enzyme. The G48V/L90M mutant had a sensitivity towards A024 and A030 similar to the G48V single mutant, with apparently no beneficial contribution for the L90M mutation, as found when it occurs as a single mutant. By contrast, the sensitivity of this double mutant to B403 was of the same order as for the wild-type, although this inhibitor was 10-fold less effective on each single mutant. A008 was the most potent inhibitor with this double mutant (K i =0.12 nM), as effective as on the wild-type enzyme, while the other cyclic inhibitors had at least two orders of magnitude higher K i values. By contrast, when L90M was combined with I84V, A008 lost potency, as did all other compounds except amprenavir and B322. Cyclic compounds were inefficient inhibitors with triple and quadruple mutants, as were linear compounds. Amprenavir was the only compound with a K i below 1 nM with the V82A/I84V/L90M triple mutant, but it lost effect once the G48V mutation was introduced. The quadruple mutant was not inhibited effectively by any of the inhibitors, the best inhibitor being amprenavir, followed by B388, ritonavir, A008 and indinavir, all having K i values below 100 nM.
Discussion
Enzyme inhibition based resistance analysis
Several different mechanisms can give rise to viral drug resistance, however, the present study is limited to one where mutations in the protease gene influence the affinity for inhibitors. It can be seen as a step-wise adaptation of the enzyme, based on a selection of mutations that reduce the binding affinity of inhibitors. First, and most obviously, residues that interact directly with the inhibitor can be substituted for residues that, for example, result in steric interference with the inhibitor, or removal of groups that contribute energetically to the binding of the inhibitor. Second, substitution of residues that do not interact with the inhibitor directly may influence binding of inhibitors by causing conformational changes or by modifying the stability of the enzyme. Although these effects may be difficult to interpret structurally, they are readily quantified as changes in K i values. However, a third and far more enigmatic effect of mutations involves changes in the catalytic efficiency of the enzyme, resulting, for example, from a changed affinity for the substrate. Therefore, when comparing the catalytic consequences of mutations that influence inhibitor binding, it is essential to account for catalytic effects of mutations, as expressed by k cat /K M . Vitality values have been used for such an analysis, and they can be seen as a kind of 'survival coefficient' under the selection pressure of a certain inhibitor (Gulnik et al., 1995) . They are thought to reveal properties that are relevant for resistance, and do not focus on affinity as such.
Mutant characterization and inhibition assay
The first step in this study was therefore to characterize the catalytic properties of all mutants under the same conditions. All the amino acid substitutions had a major effect on the kinetics for peptide hydrolysis. A dramatic decrease of k cat /K M (up to 99%) was observed for the triple and quadruple mutants. Reduced catalytic efficiencies for mutants has been observed in other studies and a comparison with previously reported kinetics for mutants indicates that the effects may vary depending on the substrates used, as well as to a certain degree on other differences in the assay used. For example, Ridky et al. (1998) reported that the G48V/L90M mutant had a similar catalytic efficiency as the wild-type, while the I84V enzyme was more efficient than the wild-type. This is not in accordance with our results. However, their studies were performed on a substrate corresponding to the wildtype CA-NCa peptide substrate (PARVL-AEAMR) while the substrate used here corresponds to the MA-CA polyprotein cleavage site (SQNY-PIVQ). The kinetic effects of using different substrates have been demonstrated for several mutants (including G48V and L90M) (Mahalingam et al., 1999) , and it has been shown that the stability of the enzyme may be influenced by the mutations. Notably, both the G48V and the L90M mutants were less stable than the wild-type enzyme, a factor that may contribute to resistance, although quantification of the effect is not trivial. In our studies we have attributed difficulties in using very low enzyme concentrations and reduced specific activities to decreased stability, a factor that influenced the accuracy in determining some kinetic constants. Finally, mutations in the protease gene, with consequences for catalytic efficiency, may be accompanied by mutations in the cleavage sites, affecting the processing of the polyprotein precursors of resistant virus (Doyon et al., 1996) . All these factors contribute to the understanding that detailed and quantitative resistance analysis is difficult and requires data obtained with the same assay using the same substrate and parent (that is, wildtype) enzyme sequence. The present dataset fulfils these requirements.
Inhibition versus resistance
The fact that all mutants displayed a reduced catalytic efficiency seems counterproductive since it makes the enzyme more sensitive to inhibitors. This implies that the reduction in affinity for the inhibitor has to be even larger, in order to compensate for this effect, or, that the enzyme has a catalytic over-capacity. In the case of the G48V/L90M substitution, the catalytic efficiency was reduced 10-fold. For the mutant to 'break even', the affinity for a certain inhibitor would thus have to be reduced 10 times. However, using A008 as an example, the K i value is similar for the wild-type and mutant enzyme, indicating that this mutation is not likely to result in resistance towards A008. This finding is also reflected in a low vitality value (0.082). In contrast, A008 has a 10-fold higher K i value for the L90M single mutant than for the wild-type enzyme, which is not sufficient to overcome the smaller reduction in catalytic efficiency for this mutant. In this case, resistance is more likely to result from this mutation (vitality value 2.8). The situation becomes more pronounced as more residues become substituted and the triple and quadruple mutants only have 1-2% of the catalytic efficiency of the wild-type enzyme. Evidently there is more to resistance than simply reducing the affinity of the viral protease for inhibitors. Despite these aspects, to obtain information about structural features that are associated with a certain resistance profile, we focused initially on the simple kinetics of the interaction between the enzyme and inhibitors and the effects of altering the structure of both the enzymes and the inhibitors.
Structure-inhibitory relationships
Due to the asymmetric binding of cyclic sulfamides (Bäckbro et al., 1997) , the P1 and P2 side chains interact with the S1 and S2 subsites, while the side chain in the nominal P1′ position interacts with the S2′ subsite, and the nominal P2′ position with the S1′ subsite. In the current series of cyclic sulfamides, this results in a phenoxymethyl side chain in the S1 and S2′ sites and variations are made on side chains interacting in the other two subsites. The three most effective cyclic sulfamides included two symmetric compounds and one asymmetric. But since the symmetric compounds bind asymmetrically, and binding symmetry cannot be obtained with these compounds, it is of minor importance if they are structurally symmetric. Although the relative effects of structural changes were similar for the sulfamide and urea compounds, a detailed analysis of analogous compounds revealed significant differences in their resistance profiles. For example, a comparison of A008, a cyclic urea, and A021, a cyclic sulfamide with identical P1/P1′ and P2/P2′ groups, shows that they differed in their response to different mutations, consistent with different binding modes. Important insights into these differences and the basis for resistance have been obtained by analysis of the structure of the subsites in the enzyme, and by estimating how mutations would change their structural features and their interactions with the inhibitors. The S1/S1′ site is large and hydrophobic, and Van der Waals interactions are important for binding of inhibitors. Notably, an important determinant is the V82 side chain, and when valine is substituted by alanine, two methyl groups are lost. This increases the distance between the side chain and the inhibitor, resulting in decreased Van der Waals interactions and a concomitant reduction of inhibitor affinity. Within experimental error, all compounds were less inhibitory on this mutant than on the wild-type enzyme, indicating that this mutation is non-specific. Of the cyclic inhibitors studied, the cyclic ureas were more sensitive towards this mutation than the sulfamides were, likely a consequence of the different P1/P1′ groups. However, the same trend was not observed with the linear compounds: B322 and B388 having a 40, respectively 3-fold increase in K i for this mutant (compared with wild-type enzyme), but no difference in the P1/P1′ groups.
The S1/S1′ site also includes G48, even if it lacks a side chain and is situated in the flap region of the enzyme. In the G48V mutant, the introduction of the valine side chain is predicted to interact with the side chain of F53, and may thus alter the conformation or the flexibility of the flap region, including the S1/S1′ site (Hong et al., 1997) . For some inhibitors, such changes may perturb the interaction with the P1/P1′ groups in a way that influences the interaction between the central mono-or di-hydroxy moiety of the inhibitor and the D25/D25′ residues of the enzyme. The G48V mutation had a minor effect on the cyclic compounds, although the reduced affinity of the cyclic urea A008 for the L90M mutant was compensated for by G48V in the G48V/L90M double mutant. Although saquinavir is sensitive towards the G48V mutation, this is not a general feature of the linear compounds.
L90 is not directly involved in any of the subsites, making any structural interpretations difficult. However, all investigated inhibitors owe a substantial part of their effect to hydrogen binding to the catalytic carboxylate side chain(s) of D25. The side chain of L90 is situated adjacent to D25, and substituting L90 by methionine is hypothesized to have a marked steric interference with the backbone amide nitrogen of D25 due to the ε-carbon of M90. A displacement of the peptide bond would cause the side chain of D25 to move away slightly from the inhibitor. As a result, the energetic contribution of the hydrogen bond between D25 carboxylate and inhibitor may be reduced, yielding higher K i values. This is paralleled in the increased K M observed for this mutant, but identification of structural features in the inhibitors that are influenced by this effect has not been possible.
Subsites S2/S2′ include residue I84, a mutation analogous to the V82A mutation. But since only one methyl group is lost, the increase in distance can be somewhat compensated for by the fact that two methyl groups remain in the side chain. However, this mutation had a larger effect on the affinity of the cyclic compounds than the V82A mutation. Again, it is not possible to rationalize the differences observed for the Ki values of the cyclic compounds simply on the basis of the P1/P1′ group. For example, A021 and A024 have identical groups in these positions, but result in a 15-and fourfold difference in K i , respectively (compared with wild-type). Obviously other groups are involved.
Both the V82 and I84 residues have previously been associated with resistance to cyclic urea inhibitors (King et al., 1995; Hodge et al., 1996) and detailed analysis of the molecular basis of resistance for cyclic urea compounds have been published Jadhav et al., 1997) . Although our data are consistent with these previous studies, we also provide data for cyclic sulfamide inhibitors, and show that differences between these two classes of cyclic inhibitors are coherent with their different binding modes to the enzyme.
Even though the above discussion has focused on K i values, we found no additional benefit when using vitality values to identify structural features associated with a certain vitality profile. As a last resort, since it is difficult to manually detect trends and correlations in such a large and varied dataset, a multivariate analysis was performed (not shown). Again, no clear correlations were identified, indicating the complexity in extracting structure-inhibition/resistance information from this set of data. Despite the relatively extensive dataset, the limited structure-inhibitory and resistance relationships that could be identified suggests that even larger datasets have to be used to understand the structural and mechanistic features of inhibition and resistance. Also, use of alternative methods and kinetic parameters may be required. For example, the possibility of resolving the affinity of inhibitor interactions into association and dissociation rate constants (Markgren et al., 2001) is currently being applied for such purposes.
Conclusions
Although clear structure-inhibitory relationships were difficult to identify for the inhibitors studied, K i values provided information about the efficacy of a certain inhibitor on a certain mutant, and, for example, which inhibitor was most effective. In addition, the present data set is unique as it contains a large number of analogous inhibitors and a variety of reference compounds, as well as a panel of different mutants, allowing for extensive comparative structure-inhibition and resistance analysis. While it was possible to rationalize many of the changes in K i values on the basis of structural differences between the inhibitors or mutants, it has not been possible to identify general structural features associated with a certain resistance profile, and the potency of a certain inhibitor on a certain mutant must be determined in each individual case. Furthermore, the effect of combining individual mutations in multiple mutants could not be predicted, and limited conclusions about structural features associated with a certain resistance profile could be made. Obviously, designing inhibitors that are effective on wild-type enzyme as well as on mutant enzyme is considerably more complicated than simply compensating structurally in the inhibitor for structural changes that result in the enzyme from mutations. The non-additivity of multiple interactions and non-identical structural rearrangements in the enzyme on binding of different inhibitors are two major factors that prevent a simple analysis. Design and evaluation of inhibitors of the resistant forms of the enzyme must therefore be directed at the target mutant.
